Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Established Drugs’ Group Boots Up with 6 Firms Plus One Organization
September 14, 2021
- PhRMA Hails Japan's New Pharma Industry Vision
September 14, 2021
- JMA Think Tank Urges Discussions to Prep for Aducanumab Approval
September 8, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
- EFPIA Japan Issues Viewpoint on Cost Effectiveness Assessment System
August 31, 2021
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
- COVID-19 Oxygen Stations Should Provide Corticosteroids and Anticoagulants Too: JMA Executive
August 24, 2021
- New Established Medicines’ Association to Discuss Info Transfer Rules for LLP Withdrawals
August 20, 2021
- New Established Drugs’ Group Places Top Priority on Stable Generic Supply; Research-Driven and Foreign Firms to Join
August 20, 2021
- Generic Use Rate at 79.4% in FY2020, Up 2.5 Points: JGA
August 3, 2021
- New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
July 30, 2021
- JPMA Reprimands Meiji Pharma over Kobayashi Kako Issue
July 16, 2021
- Hiroyuki Kawabata Joins PhRMA as Sr. Assistant Japan Representative
July 16, 2021
- Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
July 14, 2021
- Japan Patient Advocates Want Drugs for Later-Stage Alzheimer’s
July 13, 2021
- New Trade Group for Established Drugs to Launch in Japan
July 13, 2021
- FIRM Calls for Separate Pricing System for Regenerative Medicine Products: Chair
July 13, 2021
- JMA Frets Pricey Dementia Meds, to Explore Ways to Keep Universal Coverage
July 9, 2021
- High-Priced Drugs Should Be Discussed Carefully Based on Characteristics of Diseases and Treatments: JMA Exec
July 1, 2021
- More than 80% of Pharmacists Feel Impact of Generic Supply Delays on Business: Survey
June 23, 2021
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…